Elizabeth Holmes has been sentenced to just over 11 years in prison for defrauding investors by falsely claiming her technology could detect diseases from a drop of blood.
The sentencing of the former Theranos CEO marks the end of the young founder’s Silicon Valley saga—one in which she wooed investors with empty promises and idealism and raked in hundreds of millions of dollars. And it’s a case that could have an impact on how investors evaluate new startups, experts say. Many founders have used hyperbole to describe their visions and raise money, but criminal charges of fraud are rare.
“She pushed the envelope a little too far,” says Anat Alon-Beck, a
→ Continue reading at WIRED
